Progyny
PGNY
Market cap $1.22B

14.34 USD

+0.15

1.06%

At close Dec 20, 4:00 PM EST

After hours

14.33

-0.01

0.07%

1 day

1.06%

5 days

-1.51%

1 month

2.58%

3 months

-13.72%

6 months

-43.41%

Year to date

-61.46%

1 year

-60.57%

5 years

-39.08%

10 years

-10.04%

About: Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.

Employees: 566

Healthcare Miscellaneous Health & Allied Services

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

43% more call options, than puts

Call options by funds: $3.47M | Put options by funds: $2.43M

0% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 96

1.29% less ownership

Funds ownership: 95.57% [Q2] → 94.27% (-1.29%) [Q3]

13% less funds holding

Funds holding: 322 [Q2] → 281 (-41) [Q3]

41% less first-time investments, than exits

New positions opened: 60 | Existing positions closed: 101

47% less capital invested

Capital invested by funds: $2.6B [Q2] → $1.38B (-$1.22B) [Q3]

57% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 3 (-4) [Q3]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

19%

upside

Avg. target

$19.33

35%

upside

High target

$25

74%

upside

6 analyst ratings

3 positive

50%

3 neutral

50%

0 negative

0%

JP Morgan Anne Samuel 41% 1-year accuracy 14 / 34 met price target	19%upside $17	Neutral Downgraded	2 Dec 2024
Barclays Sarah James 23% 1-year accuracy 30 / 130 met price target	19%upside $17	Overweight Maintained	14 Nov 2024
B of A Securities Michael Cherny 58% 1-year accuracy 19 / 33 met price target	46%upside $21	Buy Maintained	13 Nov 2024
Canaccord Genuity Richard Close 50% 1-year accuracy 13 / 26 met price target	19%upside $17	Hold Maintained	13 Nov 2024
Truist Securities Jailendra Singh 14% 1-year accuracy 5 / 35 met price target	33%upside $19	Hold Downgraded	13 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about PGNY published over the past 30 days

PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders

SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders

CNBC Television

Four hidden gems in the stock market from a five-star fund manager

Investors might be well served by expanding beyond the S&P 500.

Four hidden gems in the stock market from a five-star fund manager

Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders

Progyny: Rating Downgrade On Uncertain Growth Outlook

I recommend downgrading Progyny from buy to hold due to a loss of confidence in its growth outlook and increased uncertainty. PGNY's Q3 2024 results were disappointing, with revenue and margins falling short of expectations, leading to lowered FY24 guidance. Declines in ART cycles and a weaker 2024 sales season raise concerns about underlying demand, despite potential upsides from upselling adjacent solutions.

Progyny: Rating Downgrade On Uncertain Growth Outlook

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares.

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

Progyny, Inc. to Present at Jefferies London Healthcare Conference

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT (3:00 a.m. EST).

Progyny, Inc. to Present at Jefferies London Healthcare Conference

The Motley Fool

Why Progyny Stock Crashed Today

Why Progyny Stock Crashed Today

Why Progyny Stock Crashed Today

See News Rankings

Charts implemented using Lightweight Charts™